The Future of Peptide Compounding Is on the Agenda Next Week

What the FDA's July PCAC meeting could mean for compounders

Next week, the U.S. Food and Drug Administration (FDA) will convene its Pharmacy Compounding Advisory Committee (PCAC) to evaluate several peptide substances nominated for inclusion on the 503A Bulks List.

While the discussions may appear highly technical, their impact could extend well beyond the meeting room. The committee's recommendations may help shape the future of peptide compounding, influence patient access, and inform how emerging peptide therapies are evaluated in the years ahead.

As clinical and scientific interest in peptide therapies continues to expand, regulators are increasingly evaluating how these substances should be considered within the framework of pharmaceutical compounding. The July PCAC meeting represents an important milestone in that ongoing process.

For pharmacists, physicians, and healthcare professionals, this is an opportunity to better understand how scientific evidence, clinical need, and regulatory oversight come together to shape the future of compounding.

Understanding PCAC and its role

The Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory committee that provides the U.S. Food and Drug Administration (FDA) with scientific, technical, and medical advice on issues related to human drug compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Its role is to help inform FDA decision-making by providing expert recommendations based on the available evidence. 

The committee is composed of experts in pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties, including representatives from organizations such as the United States Pharmacopeia (USP) and the National Association of Boards of Pharmacy (NABP), as well as patient and public health representatives. Depending on the topic under review, the committee evaluates scientific, technical, and clinical evidence and discusses factors such as safety, clinical need, and the availability of therapeutic alternatives. 

While the committee's recommendations are influential, they are advisory rather than binding. The FDA considers the committee's recommendations alongside public comments, agency review, and other available scientific evidence before making final regulatory decisions.

What is at stake for Compounders?

For compounders, the significance of this meeting marks the official start of the regulatory path towards the evaluation and recommendations for inclusion to the bulk drug substance. This is the first stage in the regulatory process which will determine if and which peptide substances may become available for compounding, and indirectly also guide future scientific research and investment, all in helping to shape patient access for years to come.

If a peptide is ultimately added to the FDA's 503A Bulks List following the agency's review and rulemaking process, licensed 503A pharmacies may be permitted to compound it from bulk active pharmaceutical ingredients (APIs), where appropriate.

It's important to remember that the July PCAC meeting is not the final step. Following the committee's recommendations, the FDA will continue its review before making any regulatory decisions through its established rulemaking process. While that process may take time, the discussions held next week represent an important milestone in how these peptide substances are evaluated.

Peptide substances expected to be discussed

During the July 23–24 meeting, the committee will discuss seven peptide-related bulk drug substances being considered for inclusion on the 503A Bulks List. Each substance will be evaluated for one or more specific clinical uses identified by the FDA.

Each peptide-related bulk drug substance will be evaluated independently based on the available scientific evidence, the clinical need for compounding, and other factors considered by the committee. Following its review, the committee will make recommendations to the FDA, which will consider this input alongside public comments and additional scientific evidence as part of its regulatory decision-making process. 

Expanding access must be matched by quality

Regulatory discussions often focus on whether a substance should be compounded.

Equally important is the quality of ingredients for the compounded formulations.

The rapid growth of peptide therapies has brought increased attention to the quality of the ingredients used in pharmaceutical compounding, an area of utmost importance and necessity, without compromise. Expanding therapeutic access must be matched by access to pharmaceutical-quality APIs supported by appropriate quality systems, manufacturing controls, analytical testing, documentation, and traceability.

The role of industry advocacy

One of the strengths of the FDA's review process is that it encourages participation from stakeholders across the pharmaceutical compounding community. Public comments and perspectives from healthcare professionals, researchers, patients, and industry help provide valuable context that supports a well-informed regulatory process.

As part of its ongoing commitment to advancing pharmaceutical compounding, Medisca submitted comments to the FDA during the public consultation period. Our submission focused on the importance of a robust, reliable, and transparent pharmaceutical ingredient supply chain, highlighting the critical role that supplier qualification, quality systems, traceability, and supply chain integrity play in supporting responsible compounding and maintaining access to high-quality pharmaceutical ingredients.

Rather than commenting on the scientific evaluation of the peptide substances under review, our submission emphasized the foundational importance of a trusted supply chain in helping compounders consistently access quality ingredients that support patient care.

We believe meaningful progress is achieved when regulators, healthcare professionals, researchers, patients, and industry each contribute their expertise to support informed, evidence-based regulatory decision-making.

Follow the discussion

The FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet July 23–24, 2026, and the sessions will be available to the public via live webcast. 

We encourage pharmacists, healthcare professionals, and industry stakeholders to participate in the process by:

1. Reviewing the FDA meeting agenda and briefing documents to better understand the peptide substances under review and the scientific evidence being considered.

→ FDA PCAC Meeting Page & Event Materials

→ FDA Public Docket & Briefing Documents

2. Submitting comments to the FDA docket by July 22, 2026. Your perspective helps ensure the voices of compounders, healthcare professionals, and patients are considered as part of the regulatory process.

→ Submit Comments to the FDA Docket

3. Tuning in to the live webcast on July 23–24 to follow the committee's discussions and recommendations in real time. The webcast link will be posted on the FDA event page no later than two business days before the meeting.

4. Following the FDA's review process beyond the meeting, as the committee's recommendations represent one step in the agency's broader regulatory decision-making process.

The future of pharmaceutical compounding is shaped by scientific evidence, thoughtful discussion, and industry participation. By staying informed and engaging in the regulatory process, pharmacists and healthcare professionals can help support the continued advancement of personalized medicine.

References

Food and Drug Administration (2026) July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Available at: FDA Advisory Committee Calendar 

Food and Drug Administration (2026) Bulk Drug Substances Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: FDA Section 503A Bulks Guidance 

Food and Drug Administration (2026) FDA to Compounders: Know Your Bulks and Excipients Suppliers. Available at: FDA Supplier Guidance 

Office of the Federal Register (2026) Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments. Available at: Federal Register Notice

Disclaimer: This article is intended for educational and informational purposes only. It discusses industry-wide events and does not provide medical advice, treatment recommendations, or clinical guidance. Healthcare decisions should always be made in consultation with qualified healthcare professionals.